User menu

Molecular imaging of cell transplantation in Parkinson's disease.

Bibliographic reference Vander Borght, Thierry. Molecular imaging of cell transplantation in Parkinson's disease.. In: European journal of nuclear medicine and molecular imaging, Vol. 33, no. 4, p. 403-6 (2006)
Permanent URL http://hdl.handle.net/2078.1/29650
  1. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301
  2. Lindvall O, Bjorklund A. Cell therapy in Parkinson’s disease. NeuroRx 2004;1:382–393
  3. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci 2005;28:86–92
  4. Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, et al. Neural transplantation for the treatment of Parkinson’s disease. Lancet Neurol 2003;2:437–445
  5. Redmond DE Jr. Cellular replacement therapy for Parkinson’s disease—where we are today? Neuroscientist 2002;8:457–488
  6. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson’s disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996;370:203–230
  7. Rauch RA, Markham CH, Rand RW, Becker DP, Lufkin RB. MR imaging findings after transplant surgery for Parkinson disease. J Magn Reson Imaging 1994;4:19–24
  8. Ross BD, Hoang TQ, Bluml S, Dubowitz D, Kopyov OV, Jacques DB, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999; 12: 221–236
  9. Brooks DJ. Positron emission tomography imaging of transplant function. NeuroRx 2004;1:482–491
  10. Pogarell O, Koch W, Gildehaus FJ, Kupsch A, Lindvall O, Oertel WH, et al. Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (in press). DOI 10.1007/s00259-005-0032-z
  11. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 2003;184:S68–S79
  12. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 2005;128:2777–2785
  13. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in parkinsonian syndromes: from the lesion to its consequences. Neuroimage 2004;23:1–16
  14. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson’s disease. Ann Neurol 1990;28:799–804
  15. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577–583
  16. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol 1996;40:873–884
  17. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996;23:467–471
  18. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16: 3507–3510
  19. Guilarte TR, Nihei MK, McGlothan JL, Howard AS. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 2003;122:499–513
  20. Naudon L, Raisman-Vozari R, Edwards RH, Leroux-Nicollet I, Peter D, Liu Y, et al. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur J Neurosci 1996;8:842–846
  21. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 2001;296:762–767
  22. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE , et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000;47:493–503
  23. Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 2002;59:580–586
  24. Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, et al. Transplantation in Parkinson’s disease: PET changes correlate with the amount of grafted tissue. Mov Disord 2003;18:928–932
  25. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995;38:580–588
  26. Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689–695
  27. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 1999;2:1137–1140
  28. Andringa G, Drukarch B, Bol JG, de BK, Sorman K, Habraken JB, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson’s disease. Neuroimage 2005;26:1150–1158
  29. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005;57:168–175
  30. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004;14:715–719
  31. Doder M., Rabiner E. A., Turjanski N., Lees A. J., Brooks D. J., Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study, 10.1212/01.wnl.0000031424.51127.2b
  32. Boucai L, Cerquetti D, Merello M. Functional surgery for Parkinson’s disease treatment: a structured analysis of a decade of published literature. Br J Neurosurg 2004;18:213–222
  33. Hagell Peter, Brundin Patrik, Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease, 10.1093/jnen/60.8.741
  34. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996;19:102–109
  35. Sortwell CE. Strategies for the augmentation of grafted dopamine neuron survival. Front Biosci 2003;8:s522–s532